Drug Profile
Research programme: antiviral therapeutics - Ennaid Therapeutics
Latest Information Update: 08 Apr 2020
Price :
$50
*
At a glance
- Originator Ennaid Therapeutics
- Class Antivirals; Peptides
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Suspended Dengue; Encephalitis; Hepatitis C; West Nile virus infections; Yellow fever; Zika virus infection
Most Recent Events
- 02 Apr 2020 Suspended - Preclinical for Dengue in USA (Parenteral) for strategic diversion of focus on COVID-2019 therapeutic
- 02 Apr 2020 Suspended - Preclinical for Encephalitis in USA (Parenteral) for strategic diversion of focus on COVID-2019 therapeutic
- 02 Apr 2020 Suspended - Preclinical for Hepatitis C in USA (Parenteral) for strategic diversion of focus on COVID-2019 therapeutic